福瑞达：公司在研产品乌帕替尼缓释片待完成全部研究工作后近期将提交国家局审批

Group 1 - The core point of the article is that the company, Furuida, is preparing to submit its research product, Upatinib sustained-release tablets, for approval after completing all necessary research work [2] - Upon passing the review, the company will obtain a drug production license, allowing the product to be available for clinical use [2]